Analysts Offer Predictions for AKBA Q1 Earnings

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Akebia Therapeutics in a report issued on Tuesday, November 11th. HC Wainwright analyst M. Caufield expects that the biopharmaceutical company will earn $0.02 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share.

Other analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Akebia Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Wall Street Zen upgraded shares of Akebia Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akebia Therapeutics in a report on Wednesday, October 8th. Finally, BTIG Research cut their price objective on shares of Akebia Therapeutics from $10.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Akebia Therapeutics Stock Performance

Shares of NASDAQ:AKBA opened at $1.81 on Wednesday. The business’s 50-day simple moving average is $2.73 and its 200 day simple moving average is $3.10. The company has a market cap of $479.91 million, a P/E ratio of -10.65 and a beta of 0.62. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.84 and a current ratio of 1.98. Akebia Therapeutics has a one year low of $1.52 and a one year high of $4.08.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Empirical Asset Management LLC bought a new stake in shares of Akebia Therapeutics in the 3rd quarter valued at approximately $55,000. Citigroup Inc. increased its stake in Akebia Therapeutics by 1,324.7% during the third quarter. Citigroup Inc. now owns 1,916,692 shares of the biopharmaceutical company’s stock valued at $5,233,000 after purchasing an additional 1,782,162 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Akebia Therapeutics during the third quarter worth $498,000. Vanguard Group Inc. lifted its position in shares of Akebia Therapeutics by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 15,547,508 shares of the biopharmaceutical company’s stock worth $42,445,000 after buying an additional 936,042 shares during the last quarter. Finally, Profund Advisors LLC boosted its holdings in shares of Akebia Therapeutics by 88.8% in the 3rd quarter. Profund Advisors LLC now owns 103,974 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 48,912 shares during the period. Institutional investors own 33.92% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.